Real-World Patterns in Alzheimer's Treatment

Summary

NeuroDiscovery AI presented insightful research at the 19th International Conference on Alzheimer's and Parkinson's Diseases (ADPD) in Copenhagen, Denmark. The study analyzed real-world data from 794 patients initiating donanemab treatment, providing critical insights into diagnostic pathways, biomarker testing patterns, and treatment timelines in clinical practice.

Key Findings

PET scan remained the dominant amyloid confirmation method (68.5%), with blood-based biomarkers used in only 9.3% of patients

Among patients with MMSE scores, ~74% fell in the MCI to mild AD range, confirming early-stage treatment intent

Comorbidity burden was low - 86.4% had a Charlson Comorbidity Index of 0-1

Diagnostic workup began well before treatment, with a mean of ~237 days from earliest biomarker to first infusion

View Poster

Poster ID

P-325

Conference

ADPD 2026

Authors

Ann HartryDrew SpargoVamsi Chandra KasivajjalaAkash BhushanAparajeeta PriyadarasaniAnand Kumar Srirampurapu

Affiliation

Eli Lilly and Company & NeuroDiscovery AI Inc.

Stay Informed

Subscribe to our research newsletter for updates on new datasets, research findings, and collaboration opportunities